Article Sidebar
Main Article Content
Abstract
RÉSUMÉ
Introduction. Il s'agissait d'analyser les effets du tériparatide sur l'ostéonécrose de la mâchoire liée à l'alendronate chez les rats. Matériaux et méthodes. Il s’agissait d’une étude préclinique de rats mâles wistar, menée sur une durée de 6 mois à l’animalerie de la Faculté de Médecine et des Sciences biomédicale de Yaoundé. Les rats sélectionnés ont reçu per os de l’alendronate à 0,1 mg/kg /semaine pendant 8 semaines. A la 8ième semaine, les rats atteints d’une ostéonécrose des mâchoires de stade 2 et 3 ont été inclus et répartis en groupes 1 et 2 (tériparatide en sous cutanée à 10 et 20 µg/kg 2 fois par semaine pendant 8 semaines) et groupe 3 (sérum physiologique en sous cutanée). À la 16ième semaine, en plus d'un contrôle clinique, les rats ont été sacrifiés et les mâchoires ont été insérées dans la résine polyacrylique pour une tomodensitométrie. Résultats. 44 rats ont été inclus et répartis aléatoirement en 3 groupes soit 30 dans le groupe 1 et 2 et 14 dans le groupe 3. Au cours de la 16ième semaine expérimentale 12 rats du groupe 1 avec un stade 2 et 3 d’ONM ont présenté une amélioration clinique de la maladie du stade 2 au stade 1. Dans le groupe témoin, seulement 3 rats ont montré une progression du stade 3 vers le stade 2. Conclusion. Le tériparatide administré en intermittence pourrait être un traitement efficace dans la résolution de l’ostéonécrose des mâchoires.
ABSTRACT
Introduction. The aim of the study was to investigate the effects of teriparatide on alendronate-related osteonecrosis of the jaw in rats. Materials and methods. This was a preclinical study of male wistar rats, conducted over a period of 6 months at the animal house of the Faculty of Medicine and Biomedical Sciences, Yaounde. The selected rats received alendronate 0.1 mg/kg/week for 8 weeks. At week 8, rats with stage 2 and 3 osteonecrosis of the jaws were included and divided into groups 1 and 2 (subcutaneous teriparatide at 10 and 20 µg/kg twice a week for 8 weeks) and group 3 (subcutaneous saline). At week 16, in addition to a clinical check-up, the rats were sacrificed and the jaws were inserted into the polyacrylic resin for a CT scan. Results. 44 rats were included and randomly divided into 3 groups: 30 in group 1 and 2 and 14 in group 3. During the 16th experimental week 12 rats in group 1 with stage 2 and 3 ONM showed clinical improvement of the disease from stage 2 to stage 1. In the control group only 3 rats showed progression from stage 3 to stage 2. Conclusion. Teriparatide administered intermittently may be an effective treatment for the resolution of osteonecrosis of the jaws.
Keywords
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- Kim SS, Jeong SP, Park BS, Kim IR. Melatonin Attenuates RANKL-Induced Osteoclastogenesis via Inhibition of Atp6v0d2 and DC-STAMP through MAPK and NFATc1 Signaling Pathways. Molecules. MDPI; 2022;27.
- Kim J-Y, Song HC, Jee H-G. Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients. Clin Interv Aging. 2019;14:797–804.
- Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clinics in Geriatric Medicine. 2003;19:415–32.
- Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93:1583–7.
- Ejersted C, Andreassen TT, Oxlund H, Jørgensen PH, Bak B, Häggblad J, et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res. 1993;8:1097–101.
- Lawrence JP, Ennis F, White AP, Magit D, Polzhofer G, Drespe I, et al. Effect of daily parathyroid hormone (1–34) on lumbar fusion in a rat model. The Spine Journal. Elsevier; 2006;6:385–90.
- Bazin J-E, Constantin J-M, Gindre G. Article spécial Laboratory animal anaesthesia: influence of anaesthetic protocols on experimental models. Annales Françaises d’Anesthésie et de Réanimation. 2004;23:811–8.
- Barba-Recreo P, Burgueño M, Del Castillo Pardo de Vera JL, García-Arranz M, Yébenes L. Zoledronic acid – Related osteonecrosis of the jaws. Experimental model with dental extractions in rats. Journal of Cranio-Maxillofacial Surgery. Elsevier Ltd; 2013;42:744–50.
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. Journal of Oral and Maxillofacial Surgery. American Association of Oral and Maxillofacial Surgeons; 2014;72:1938–56.
- Bagger LW, Hansen PKD, Schwarz P, Nielsen BR. Republished: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis. Drug and Therapeutics Bulletin. 2021;59.
- Çamili Y, Malkoç S, Taşlidere A, Ileri Z, Guler OC. Effects of teriparatide on bone formation in rats with experimentally induced premaxillary expansion. Dental Press Journal of Orthodontics. SciELO Brasil; 2022;27.
- Dayisoylu EH, Şenel FÇ, Üngör C, Tosun E, Çankaya M, Ersöz S, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. International journal of oral and maxillofacial surgery. Int J Oral Maxillofac Surg; 2013;42:1475–80.
- Goltzman D. Physiology of Parathyroid Hormone. Endocrinol Metab Clin North Am. 2018;47:743–58.
- Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. J Bone Miner Res; 1992;7:65–72.
- Deal C. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep. 2004;6:49–58.
- Dempster D, Compston J, Drezner M, Glorieux F, Kanis J, Malluche H. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28.
- Dayisoylu EH, Şenel FÇ, Üngör C, Tosun E, Çankaya M, Ersöz S, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. International journal of oral and maxillofacial surgery. Int J Oral Maxillofac Surg; 2013; 42:1475–80.
References
Kim SS, Jeong SP, Park BS, Kim IR. Melatonin Attenuates RANKL-Induced Osteoclastogenesis via Inhibition of Atp6v0d2 and DC-STAMP through MAPK and NFATc1 Signaling Pathways. Molecules. MDPI; 2022;27.
Kim J-Y, Song HC, Jee H-G. Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients. Clin Interv Aging. 2019;14:797–804.
Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clinics in Geriatric Medicine. 2003;19:415–32.
Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93:1583–7.
Ejersted C, Andreassen TT, Oxlund H, Jørgensen PH, Bak B, Häggblad J, et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res. 1993;8:1097–101.
Lawrence JP, Ennis F, White AP, Magit D, Polzhofer G, Drespe I, et al. Effect of daily parathyroid hormone (1–34) on lumbar fusion in a rat model. The Spine Journal. Elsevier; 2006;6:385–90.
Bazin J-E, Constantin J-M, Gindre G. Article spécial Laboratory animal anaesthesia: influence of anaesthetic protocols on experimental models. Annales Françaises d’Anesthésie et de Réanimation. 2004;23:811–8.
Barba-Recreo P, Burgueño M, Del Castillo Pardo de Vera JL, García-Arranz M, Yébenes L. Zoledronic acid – Related osteonecrosis of the jaws. Experimental model with dental extractions in rats. Journal of Cranio-Maxillofacial Surgery. Elsevier Ltd; 2013;42:744–50.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. Journal of Oral and Maxillofacial Surgery. American Association of Oral and Maxillofacial Surgeons; 2014;72:1938–56.
Bagger LW, Hansen PKD, Schwarz P, Nielsen BR. Republished: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis. Drug and Therapeutics Bulletin. 2021;59.
Çamili Y, Malkoç S, Taşlidere A, Ileri Z, Guler OC. Effects of teriparatide on bone formation in rats with experimentally induced premaxillary expansion. Dental Press Journal of Orthodontics. SciELO Brasil; 2022;27.
Dayisoylu EH, Şenel FÇ, Üngör C, Tosun E, Çankaya M, Ersöz S, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. International journal of oral and maxillofacial surgery. Int J Oral Maxillofac Surg; 2013;42:1475–80.
Goltzman D. Physiology of Parathyroid Hormone. Endocrinol Metab Clin North Am. 2018;47:743–58.
Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. J Bone Miner Res; 1992;7:65–72.
Deal C. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep. 2004;6:49–58.
Dempster D, Compston J, Drezner M, Glorieux F, Kanis J, Malluche H. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28.
Dayisoylu EH, Şenel FÇ, Üngör C, Tosun E, Çankaya M, Ersöz S, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. International journal of oral and maxillofacial surgery. Int J Oral Maxillofac Surg; 2013; 42:1475–80.